Menu
X
    Madhura Dethe
  • Date: November 13, 2020
    • Categories: Health

Epygenix declares 1st patient dosed successfully in EPX-100’s Phase 2

Biopharmaceutical major, Epygenix Therapeutics, Inc., has reportedly announced its success with the dosing of the first patient in a randomized, placebo-controlled, double-blind, Phase 2 trial of EPX-100 as an Adjunctive Therapy for children diagnosed with Dravet Syndrome. The trial is meant for assessing the safety and efficiency of EPX-100 in children having Dravet Syndrome and the company is in the process of recruiting 24 patients for the completion of this study.



According to Epygenix Chair, Alex Yang, J.D., LLM, owing to its superb safety profile and robust science background, the company is cautiously optimistic that EPX-100 will bring out excellent results in this study and take another pace towards the development of the best-in-class refractory epilepsies drug.



Epygenix President and CEO, Dr. Hahn-Jun Lee, M.Sc., Ph.D., has also expressed the company’s pleasure in the announcement of these results. Lee has further opined that first patient dosing is a highly significant clinical milestone of EPX-100 in Dravet patients. The company has made substantial efforts so far and will consistently work to gain meaningful clinical results for these patients, added Lee.



Dravet Syndrome is a lifelong, rare, and catastrophic form of epilepsy that commences in the first year of life with prolonged or frequent seizures. Increased mortality, intellectual disability, behavioral abnormalities, and gait and motor dysfunction are commonly observed in patients with the advancement of this disease.



For the uninitiated, Epygenix Therapeutics, Inc., specializes in the discovery and development of drugs for the treatment of intractable and rare genetic epilepsy in childhood, comprising Dravet Syndrome. The company is presently working towards the development of EPX-100, EPX-200, and EPX-300 drug candidates. These candidates are supposed to abolish electrographic seizure activity and convulsive behavior, discovered in a zebrafish Dravet Syndrome model, which shows considerable resemblance to human pathology and further authenticates its validity by the human efficacy with EPX-300 and EPX-200.



 



Source Credits:



https://www.prnewswire.com/news-releases/epygenix-therapeutics-announces-first-patient-successfully-dosed-in-phase-2-study-for-the-treatment-of-dravet-syndrome-with-epx-100-301171444.html
Madhura Dethe:

Having pursued a post graduate degree in English Literature, Madhura’s interest naturally drifted toward writing. Presently, she works as an associate content writer for lunchwithapunch.com and pens down insightful articles on healthcare, technology, and business trends. Her other interests comprise reading, sketching, and classical dance.
    Related Post